3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
5
Completed
4
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Uterine Cervical Neoplasms
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumor
1
Rectal Neoplasms
1
Oligometastatic Prostate Cancer
1
Neoplasms
1
Metastatic Urothelial Cancer
1
Lung Diseases
1
Locally Advanced Cervical Cancer
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Erythrocytosis, Familial, 4
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoid Tumor
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Advanced Solid Tumors
1
Advanced Solid Tumor
1
Interventions
pembrolizumab
115
Carboplatin
103
Pemetrexed
90
Cisplatin
58
Paclitaxel
47
osimertinib
41
Drug Therapy
40
Nivolumab
39
Docetaxel
35
Specimen Handling
33
Magnetic Resonance Spectroscopy
28
Bevacizumab
26
durvalumab
23
Gemcitabine
22
cemiplimab
21
Radiotherapy
20
130-nm albumin-bound paclitaxel
20
Radiosurgery
19
tislelizumab
18
atezolizumab
17
aflutinib
15
Cetuximab
15
Immunotherapy
14
Immune Checkpoint Inhibitors
14
Platinum Compounds
13
Ipilimumab
13
Biopsy
12
Standard of Care
11
Surgical Procedures, Operative
10
Injections
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Non-Small-Cell Lung
×
zimberelimab
×
Clear all
NCT06431633
2026-05-18
ARIAN
Fundación GECP
Phase 3
Recruiting
129 enrolled